Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 4/20 | 0.55 |
| ▸ | LOX | P28300 | 2/20 | 0.55 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | F10 | P00742 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1490845 | 0.87 | L3MBTL1 (0.61) | ALDH1A1HPGDGAAMAPTNPC1 | |
| SCHEMBL30098865 | 0.87 | ALDH1A1 (0.73) | ALDH1A1HPGDGAAMAPTNPC1 | |
| SCHEMBL177578 | 0.84 | SMN1; SMN2 (0.70) | ALDH1A1HPGDGAAMAPTSMN1; SMN2 | |
| SCHEMBL3995095 | 0.84 | SMN1; SMN2 (0.52) | ALDH1A1HPGDGAAMAPTNPC1 | |
| SCHEMBL4938777 | 0.82 | GUSB (0.51) | ALDH1A1HPGDGAAMAPTNPC1 | |
| SCHEMBL4046701 | 0.80 | KMT2A (0.69) | HPGDGAAKMT2ALMNAMEN1 | |
| SCHEMBL8737464 | 0.80 | SMN1; SMN2 (0.61) | ALDH1A1HPGDLOXLOXL2GAA | |
| SCHEMBL23471363 | 0.79 | HPGD (0.60) | ALDH1A1HPGDLOXLOXL2GAA | |
| SCHEMBL23470996 | 0.79 | HPGD (0.65) | ALDH1A1HPGDLOXLOXL2MAPT | |
| SCHEMBL12867 | 0.79 | NPC1 (0.64) | ALDH1A1HPGDGAANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130012485-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2013-01-10 | — | — | US | disclosed |
| EP-2124913-A1 | 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS | Novartis AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008077597-A1 | 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS | NOVARTIS AG (CH) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012485-A1 | ORGANIC COMPOUNDS | DPP4, DPP3, DPP7 | ALDH1A1 304/4885HPGD 2114/4885LOX 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.